U.S. Markets closed

Cyclacel Pharmaceuticals, Inc. (CYCCP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
6.500.00 (0.00%)
At close: 9:30AM EDT
People also watch
CYCCTROVWADXSWCYTXWKONE

Cyclacel Pharmaceuticals, Inc.

200 Connell Drive
Suite 1500
Berkeley Heights, NJ 07922
United States
908-517-7330
http://www.cyclacel.com

Sector
Industry
Full Time Employees13

Key Executives

NameTitlePayExercisedAge
Mr. Spiro George RombotisCEO, Pres & Exec. Director731.96kN/A58
Mr. Paul McBarronCFO, COO, Exec. VP of Fin., Sec. & Exec. Director356.48kN/A56
Dr. Judy H. Chiao M.D.VP of Clinical Devel. & Regulatory Affairs484.78kN/A57
Prof. David Glover Ph.D., FRS FRSEChief ScientistN/AN/A69
Dr. Susan Davis Ph.D.Sr. Director of Bus. Devel. and Project ManagementN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company’s oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes. Its oncology development programs also comprise Seliciclib, a first-generation cyclin dependent kinase (CDK) inhibitor that is in phase I/II combination study with sapacitabine for BRCA mutations; and CYC065, a second generation CDK inhibitor, which is in Phase I clinical trial for solid tumors. In addition, the company’s oncology development programs include CYC140, a polo-like kinase inhibitor program that is in preclinical development stage. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.

Corporate Governance

Cyclacel Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.